These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
171 related articles for article (PubMed ID: 31893236)
1. Viral hepatitis C treatment shortening - what is the limit? Zarębska-Michaluk D Clin Exp Hepatol; 2019 Nov; 5(4):265-270. PubMed ID: 31893236 [TBL] [Abstract][Full Text] [Related]
2. Impact of interferon free regimens on clinical and cost outcomes for chronic hepatitis C genotype 1 patients. Younossi ZM; Singer ME; Mir HM; Henry L; Hunt S J Hepatol; 2014 Mar; 60(3):530-7. PubMed ID: 24269472 [TBL] [Abstract][Full Text] [Related]
3. Pharmacogenetics of hepatitis C: transition from interferon-based therapies to direct-acting antiviral agents. Kamal SM Hepat Med; 2014; 6():61-77. PubMed ID: 25114601 [TBL] [Abstract][Full Text] [Related]
4. Ombitasvir, paritaprevir, and ritonavir plus ribavirin for chronic hepatitis C virus genotype 4 infection in Egyptian patients with or without compensated cirrhosis (AGATE-II): a multicentre, phase 3, partly randomised open-label trial. Waked I; Shiha G; Qaqish RB; Esmat G; Yosry A; Hassany M; Soliman R; Mohey MA; Allam N; Zayed N; Asselah T; Hall C; Redman R; Mobashery N; Doss W Lancet Gastroenterol Hepatol; 2016 Sep; 1(1):36-44. PubMed ID: 28404110 [TBL] [Abstract][Full Text] [Related]
6. All Oral Interferon-free Direct-acting Antivirals as Combination Therapies to Cure Hepatitis C. Shahid I; Ibrahim MM Curr Mol Med; 2018; 18(7):409-435. PubMed ID: 30608042 [TBL] [Abstract][Full Text] [Related]
7. Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation. Shepherd J; Brodin H; Cave C; Waugh N; Price A; Gabbay J Health Technol Assess; 2004 Oct; 8(39):iii-iv, 1-125. PubMed ID: 15461877 [TBL] [Abstract][Full Text] [Related]
8. Antiviral Therapy in Patients with Hepatitis C Virus-Induced Cirrhosis. Bailly F; Pradat P; Virlogeux V; Zoulim F Dig Dis; 2015; 33(4):613-23. PubMed ID: 26159282 [TBL] [Abstract][Full Text] [Related]
9. Future perspectives: towards interferon-free regimens for HCV. Gane E Antivir Ther; 2012; 17(6 Pt B):1201-10. PubMed ID: 23186654 [TBL] [Abstract][Full Text] [Related]
10. Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation. Hartwell D; Jones J; Baxter L; Shepherd J Health Technol Assess; 2011 Apr; 15(17):i-xii, 1-210. PubMed ID: 21473834 [TBL] [Abstract][Full Text] [Related]
11. Safety and Efficacy of Elbasvir/Grazoprevir in Patients With Hepatitis C Virus Infection and Compensated Cirrhosis: An Integrated Analysis. Jacobson IM; Lawitz E; Kwo PY; Hézode C; Peng CY; Howe AYM; Hwang P; Wahl J; Robertson M; Barr E; Haber BA Gastroenterology; 2017 May; 152(6):1372-1382.e2. PubMed ID: 28193518 [TBL] [Abstract][Full Text] [Related]
12. Immunosuppressive and antiviral treatment of hepatitis C virus-associated glomerular disease: A long-term follow-up. Fabrizi F; Aghemo A; Lampertico P; Fraquelli M; Cresseri D; Moroni G; Passerini P; Donato FM; Messa P Int J Artif Organs; 2018 Jun; 41(6):306-318. PubMed ID: 29595085 [TBL] [Abstract][Full Text] [Related]
13. Current progress in the treatment of chronic hepatitis C. Alexopoulou A; Papatheodoridis GV World J Gastroenterol; 2012 Nov; 18(42):6060-9. PubMed ID: 23155334 [TBL] [Abstract][Full Text] [Related]
15. Pharmacological interventions for acute hepatitis C infection: an attempted network meta-analysis. Kalafateli M; Buzzetti E; Thorburn D; Davidson BR; Tsochatzis E; Gurusamy KS Cochrane Database Syst Rev; 2017 Mar; 3(3):CD011644. PubMed ID: 28285495 [TBL] [Abstract][Full Text] [Related]
16. [Side-effects of pegylated interferon plus ribavirin therapy with or without protease inhibitor direct acting antiviral agents during treatment of chronic hepatitis C virus infection]. Hunyady B; Kovács B; Battyáni Z Orv Hetil; 2011 Dec; 152(50):1997-2009. PubMed ID: 22112373 [TBL] [Abstract][Full Text] [Related]
17. No one size fits all-Shortening duration of therapy with direct-acting antivirals for hepatitis C genotype 1 infection. El Sherif O; Afhdal N; Curry M J Viral Hepat; 2017 Oct; 24(10):808-813. PubMed ID: 28581634 [TBL] [Abstract][Full Text] [Related]
18. Treatment of hepatitis C: a systematic review. Kohli A; Shaffer A; Sherman A; Kottilil S JAMA; 2014 Aug; 312(6):631-40. PubMed ID: 25117132 [TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of sofosbuvir-velpatasvir-voxilaprevir for re-treatment of chronic hepatitis C virus infection in patients with previous direct-acting antiviral treatment failure in Rwanda (SHARED-3): a single-arm trial. Gupta N; Manirambona L; Shumbusho F; Kabihizi J; Murangwa A; Serumondo J; Makuza JD; Nsanzimana S; Muvunyi CM; Mukabatsinda C; Musabeyezu E; Camus G; Grant PM; Kateera F Lancet Gastroenterol Hepatol; 2022 Jun; 7(6):542-551. PubMed ID: 35248212 [TBL] [Abstract][Full Text] [Related]